Dr. Cohen Vered leads the CMC development at NeuroSense Therapeutics.
She has been a development and operations executive for over 25 years, and has experience leading drug development (CMC) teams in the pharmaceutical industry, both in large multinational corporations as well as in startup environments.
Prior roles include VP CMC at NeuroDerm for 10 years, CMC at Orasis Pharmaceutical, and Head of Parenteral Dosage Forms at Teva innovative R&D for 15 years, Sharon has also been consulting many pharmaceutical companies over the past 12 years.
PhD in Biochemistry from Tel Aviv University
